On Dec. 21, 2018, the U.S. Food and Drug Administration (FDA) approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics), a CD123-directed cytotoxin, for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.
Read the FDA announcement here.
Read the Stemline Therapeutics press release here.
Posted 12/26/18
In recognition of Leukemia and Lymphoma Awareness Month, ACCC compiled a group of resources to help care teams navigate two of the most commonly diagnosed adult leukemias: acute myeloid leukemia and chronic lymphocytic leukemia.
